Guilherme Da Silva Rodrigues
1*†
Leonardo Santos Lopes da Silva
1
†
Andressa Crystine da Silva Sobrinho
1
Jonas Benjamim
2
Gabriela Ferreira Abud
3
Gabriela Ueta Ortiz
3
Ellen Cristini de Freitas
3,4
Carlos Roberto Bueno Júnior
1,4
- 1 Department of Internal Medicine, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
- 2 Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Geelong, VIC, Australia
- 3 Department of Health Sciences, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
- 4 School of Physical Education and Sport of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, Brazil
This review explores the effects of dietary polyphenols, such as resveratrol, quercetin, epigallocatechin gallate, and curcumin, on sarcopenia, with a particular focus on the underlying molecular and epigenetic mechanisms. These bioactive compounds may modulate key signaling pathways, including mTOR, NF-κB, and AMPK, while also influencing epigenetic processes such as DNA methylation, histone modifications, and microRNA regulation. Through these actions, polyphenols may reduce oxidative stress and chronic low-grade inflammation (inflammaging), enhance mitochondrial function, and contribute to the preservation of muscle mass and strength in older adults. Evidence from experimental and clinical studies investigating the impact of polyphenols on muscle health and their potential in the prevention or attenuation of sarcopenia will be discussed. In addition, current challenges and future perspectives will be addressed, emphasizing the role of epigenetic biomarkers and the potential synergy with physical exercise as part of integrated geroscience strategies to optimize muscle health during aging.
1 Introdution
Aging is accompanied by an interaction between environmental and physiological factors that favors the development of sarcopenia. In addition to lifestyle-related factors such as reduced physical activity and inadequate nutrient intake, skeletal muscle undergoes measurable structural and metabolic decline beginning in the third decade of life (Evans and Lexell, 1995), and continues to be progressively affected during aging by several biological hallmarks of aging, including epigenetic alterations such as DNA methylation drift, histone modifications, and dysregulated non-coding RNAs, which compromise its ability to regenerate and maintain functionality (Daily and Park, 2022; Wang et al., 2022). Among these, mitochondrial dysfunction, oxidative stress, epigenetic instability, and low-grade chronic inflammation stand out. Mitochondrial dysfunction impairs energy production and promotes the accumulation of reactive oxygen species (ROS), which exceed the endogenous antioxidant capacity and cause cellular damage and activation of inflammatory pathways (Napolitano et al., 2021). Systemic inflammation impairs the signaling of key anabolic pathways, such as IGF-1 and insulin, contributing to reduced protein synthesis (López-Otín et al., 2023).
Furthermore, aging is associated with anabolic resistance, characterized by a blunted response to amino acid intake and physical exercise, even under normally stimulatory conditions. Neuromuscular dysfunction, marked by the loss of alpha motor neurons and the deterioration of motor unit integrity, reduces the neural stimulus required to maintain muscle mass (Borzuola et al., 2020). The infiltration of fat into muscle tissue and increased fibrosis contribute to the decline in muscle quality, while a reduction in the number and function of satellite cells limits muscle regeneration. These multiple factors act synergistically, promoting a persistent negative protein balance that ultimately leads to the progressive loss of muscle mass and function observed in age-related sarcopenia (Chinvattanachot et al., 2024).
Given the role of inflammation and oxidative stress in the pathophysiology of sarcopenia, interventions targeting these deleterious effects of aging have emerged as promising therapeutic and prevention strategies within a multidisciplinary care framework (Hu et al., 2024). Dietary polyphenols are bioactive compounds present in plant-based foods. They are named for containing two or more phenolic hydroxyl groups. Polyphenols are broadly classified into two main categories based on their chemical structure: flavonoids and non-flavonoids. Flavonoids are further subdivided into six subclasses: (1) flavanones; (2) flavonols; (3) flavones; (4) isoflavones; (5) anthocyanins; and (6) flavan-3-ols—according to the number and type of linkages between their phenolic groups. Non-flavonoid polyphenols primarily include phenolic acids, stilbenes, lignans, coumarins, and tannins (Medoro et al., 2024).
The primary dietary sources of polyphenols are fruits and vegetables; however, their bioavailability is influenced by numerous factors. These include environmental conditions, food processing methods, gastrointestinal metabolism, particularly the action of the gut microbiota, and cellular metabolic pathways. Such factors can significantly affect the absorption, distribution, and biological activity of polyphenols within the human body (Arfaoui, 2021).
The current review aims to elucidate the potential of dietary polyphenols as a therapeutic strategy for sarcopenia by exploring the underlying molecular and cellular mechanisms. Additionally, it discusses their relevance to muscle health during aging and the challenges associated with their implementation in clinical practice.
2 Definition, diagnostic criteria, and clinical relevance of sarcopenia
According to the revised criteria of the EWGSOP2 (2019), the contemporary definition of this condition transcends the mere quantitative decrease in muscle tissue and necessarily includes a qualitative assessment that encompasses significant muscle strength loss and a marked deterioration in physical performance, particularly in the advanced stages of the disease (Sayer and Cruz-Jentoft, 2022). EWGSOP2 further categorizes sarcopenia into probable, confirmed, and severe stages, based on progressive impairments in muscle strength, mass, and physical performance.
Early identification of sarcopenia is critical for effective management, requiring the use of standardized diagnostic criteria and reliable objective assessments (Liu et al., 2024; Voulgaridou et al., 2024). Among the techniques employed, dual-energy X-ray absorptiometry (DXA) stands out for its precision in measuring skeletal muscle mass, while handgrip dynamometry represents a practical and efficient method for assessing muscle strength through handgrip strength (Liu et al., 2024; Ooi and Welch, 2024). Furthermore, functional tests such as gait speed and the chair stand test are commonly applied to evaluate overall physical performance and to detect early declines in functionality typically associated with sarcopenia (Liu et al., 2024; Voulgaridou et al., 2024).
Recent advances have explored the use of circulating biomarkers as potential complementary tools for the early diagnosis of sarcopenia; however, there is still no consensus regarding the most effective biomarkers (Veronesi et al., 2024; Lian et al., 2024). Examples include myostatin, C-reactive protein (CRP), and interleukin-6 (IL-6), although consensus is lacking on their clinical applicability. Concurrently, significant challenges persist, including the lack of universal diagnostic criteria and variability in the measurement techniques and instruments employed. To overcome these challenges, it is essential to adopt a multidimensional approach that integrates the assessment of muscle mass, strength, and physical performance, utilizing standardized methods and continuously investing in research on new biomarkers (Pedauyé-Rueda et al., 2024). This integrated strategy can substantially enhance diagnostic accuracy and promote more effective and timely interventions, ultimately improving the quality of life for older population.
2.1 Clinical, functional, and psychosocial impact of sarcopenia
The clinical impact of sarcopenia on older adults is broad and multifaceted, encompassing both direct health complications and indirect consequences that affect the prognosis of various clinical conditions (He et al., 2021; Xue et al., 2021). Aging is strongly associated with an increased prevalence of cardiovascular diseases, type 2 diabetes, and postoperative complications, leading to more frequent and prolonged hospitalizations, as well as severe complications such as hospital-acquired infections and higher mortality rates across diverse clinical settings, including oncology patients (Li et al., 2023; Wang H. et al., 2021). Although these conditions are strongly influenced by aging, the presence of sarcopenia further exacerbates clinical vulnerability, acting as an aggravating factor for multiple diseases and significantly compromising recovery and survival among older patients (Sun et al., 2022).
In addition to its impact on skeletal muscle, physiological aging induces progressive degenerative changes across the entire musculoskeletal system (Boros and Freemont, 2017). These alterations include reductions in bone mineral density that contribute to osteoporosis, as well as structural and inflammatory changes within joint tissues that promote the development of osteoarthritis (Goldring and Goldring, 2016). Together, these age-related impairments in bone and joint integrity interact with declining muscle mass and strength, compounding the risk of mobility limitations, chronic pain, falls, and functional decline (Wang et al., 2025). By understanding these interconnected processes, the multifactorial nature of musculoskeletal deterioration during senescence becomes clearer, contextualizing sarcopenia as part of a broader trajectory of tissue degeneration rather than an isolated condition (Boccardi, 2024; Larsson et al., 2019).
From a functional perspective, sarcopenia triggers a marked decline in physical capacity, particularly in mobility and postural stability, substantially increasing the risk of falls and bone fractures (Yuan and Larsson, 2023; Su et al., 2022). These are leading contributors to morbidity and mortality among older adults. This reduction in functional capacity severely compromises the autonomy of older adults, limiting their ability to independently perform basic and instrumental activities of daily living, such as dressing, eating, managing medications, and carrying out simple household tasks (Liu et al., 2023). This growing functional dependence considerably diminishes quality of life and intensifies the use of healthcare and social support services, representing a significant burden for both individuals and their families and caregivers (Izzo et al., 2021).
Moreover, the psychosocial repercussions of sarcopenia are substantial, often manifesting through social isolation, depression, and anxiety, which may be exacerbated by the perception of frailty and the progressive loss of independence (Yuan and Larsson, 2023). These psychological implications not only compromise the emotional wellbeing of older adults but also have the potential to further worsen clinical and functional outcomes, creating a vicious cycle in which physical and psychological deteriorations mutually reinforce one another (Yuan and Larsson, 2023; Chen and Wu, 2025). This reciprocal deterioration is often intertwined with frailty syndrome, further increasing vulnerability to adverse health outcomes. Therefore, a comprehensive approach to sarcopenia must incorporate integrated strategies encompassing clinical, functional, and psychosocial interventions to promote a better and more sustainable quality of life for the older population.
3 Biological, molecular and epigenetics factors involved in sarcopenia
Sarcopenia is a multifactorial condition characterized by the progressive decline in muscle mass, strength, and function with aging. Several biological and molecular factors contribute to its onset, including impaired muscle regeneration, chronic low-grade inflammation, oxidative stress, and metabolic dysfunction (He et al., 2020).
From a genetic perspective, polymorphisms in genes associated with muscle mass and function have been linked to sarcopenia risk. However, genetic factors alone do not fully explain the large interindividual variability, highlighting the crucial role of epigenetic mechanisms (Antoun et al., 2022).
Recent epigenome-wide studies demonstrate that DNA methylation is a key regulator of genes involved in muscle metabolism, myoblast differentiation, and regenerative capacity. Specific methylation signatures have been associated with appendicular lean mass, grip strength, and gait speed (Antoun et al., 2022). Differentially methylated regions are enriched in genes related to myotube fusion, oxidative phosphorylation, and voltage-gated calcium channels, indicating that epigenetic modifications affect essential pathways in muscle homeostasis.
Moreover, DNA methylation of secretory muscle factors, such as myokines, has been identified as a determinant of muscle function and a potential biomarker for early detection of sarcopenia (Li et al., 2024). This emphasizes the value of epigenetic profiling of muscle-derived secretions for diagnostic and therapeutic strategies.
Immunological mechanisms also intersect with epigenetic regulation in sarcopenia. Persistent activation of innate and adaptive immune pathways may alter DNA methylation landscapes of immune cells infiltrating skeletal muscle, thereby contributing to chronic inflammation and accelerating muscle decline (Bogucka et al., 2025; Yedigaryan et al., 2022).
Finally, combining genetic and epigenetic scores has shown greater predictive power for sarcopenia risk compared with genetic variants alone, reinforcing the role of epigenetics as a mediator between genetic predisposition and environmental exposures (He et al., 2020).
Together, these findings suggest that classical biological and molecular factors of sarcopenia should be reinterpreted through an epigenetic lens, positioning epigenetic regulation as a central link between genetics, environment, and muscle aging (Figure 1).
Figure 1. Epigenetics is a bridge between genetics and environment in the context of sarcopenia. Note Environmental factors, such as physical exercise and dietary intake, modulate epigenetic mechanisms (DNA methylation, histone modifications, and microRNAs), which in turn influence genetic regulation of muscle mass and strength. These epigenetic changes affect key biological processes, including satellite cell mediated muscle regeneration, chronic low-grade inflammation (inflammaging), and oxidative stress. The central panel illustrates muscle morphology: A: represents young muscle, while; B: represents aged muscle characterized by atrophy and impaired function. Collectively, these interactions contribute to reduced muscle mass, strength, and function, ultimately leading to sarcopenia.
4 Dietary polyphenols: properties and sources
Polyphenols are naturally occurring phytonutrients in plant-based foods and have significant antioxidant and anti-inflammatory effects on the human body (Kesh et al., 2023). These compounds provide health benefits through their high antioxidant capacity, which allows them to neutralize reactive oxygen species and modulate gene expression (Fagbohun et al., 2023). The benefits of a diet rich in polyphenols are linked to the prevention of cardiovascular and neurodegenerative diseases, cancer, and an important role in longevity (Rudrapal et al., 2022), in addition to reducing oxidative stress, which is one of the main factors in aging (Hajam et al., 2022).
There are a variety of polyphenols, totaling approximately 8,000 types (Beylerli et al., 2022). This range is divided into groups such as flavonoids, lignans, tannins, phenolic acids, and stilbenes (Ciupei et al., 2024). Despite their diversity, they share antioxidant and anti-inflammatory properties that contribute to cardiovascular and brain health (Olufunmilayo et al., 2023; Rana et al., 2022).
Regular intake of foods rich in polyphenols is associated with several benefits, such as reduced blood pressure and improved lipid profile (Rana et al., 2022; Hu, 2024). A study carried out by Karam et al., (2018) with 211 participants, aged between 50 and 80 years, used two non-consecutive 24-h recalls to estimate polyphenol intake, and the findings showed that residents of Mallorca in Spain had red wine as one of the main sources of polyphenols, and that factors such as gender, educational level, income, alcohol consumption and physical activity influenced the intake of these bioactive compounds (Karam et al., 2018). The average daily intake of polyphenols among adults and older adults in Mallorca, Spain, was 332.7 mg/day, with a median of 299 mg/day (Karam et al., 2018).
A study conducted by Miranda et al. (2016), in the city of São Paulo, Brazil, with 1,103 participants, including both adults and older individuals, used the food frequency questionnaire (FFQ) to assess the intake of foods rich in polyphenols. The results showed that the average daily intake of polyphenols was 337.5 mg/day, with coffee being the main source in this sample, contributing with 70.5% of the total intake, but highlighting other significant sources such as citrus fruits (4.6%) and tropical fruits (3.4%) (Miranda et al., 2016). Another interesting finding of the study is that older people had a significantly higher intake of polyphenols compared to younger adults (Miranda et al., 2016) (Table 1). These findings underscore how dietary patterns and cultural factors influence the primary sources and intake levels of polyphenols in different populations.
Table 1. Summary of polyphenol intake and dietary sources in various populations.
The following table concisely summarizes the main properties and health benefits of the most common polyphenols, such as catechins, resveratrol, curcumin, quercetin and epigallocatechin gallate (Table 2). We have included examples of foods that present a risk to these compounds, in addition to their effects on human health.
Table 2. Properties and benefits of polyphenols.
The interesting thing about natural foods is that, in some cases, they appear in more than one category due to their variety of bioactive compounds, so it is important to have a rich and diverse diet (Table 2).
4.1 Polyphenols in bone and joint health
Bone is a metabolically active tissue that undergoes continuous remodeling through the coordinated actions of osteoblasts, which form new bones, and osteoclasts, which resorb mineralized matrix. With aging, this coupling becomes progressively unbalanced, with a relative increase in resorption and a decline in bone formation, contributing to bone loss, microarchitectural deterioration, and increased fracture risk, particularly in postmenopausal osteoporosis. In this context, dietary polyphenols have emerged as promising adjuncts for skeletal health, since experimental and clinical studies suggest that they can modulate oxidative stress, inflammatory signaling, and key molecular pathways that regulate osteoblast and osteoclast function, thereby influencing bone remodeling and osteoporosis progression (Perrone et al., 2025).
At the cellular level, several polyphenols appear to promote an osteoanabolic profile by stimulating osteoblast proliferation, differentiation, and mineralization, while simultaneously attenuating osteoclastogenesis and bone resorption. Mechanistic studies indicate that these effects involve the regulation of osteogenic pathways such as Wnt/β-catenin and MAPK, as well as modulation of the RANKL/OPG axis and other signaling nodes that couple bone formation and resorption (Perrone et al., 2025; Li et al., 2022). In preclinical models, resveratrol is one of the best characterized compounds, showing the capacity to improve bone microarchitecture and turnover markers in aging-related osteoporosis. These benefits have been linked to an upregulation of FoxO1 and SIRT1 expression and a more favorable RANKL/OPG balance in bone tissue, supporting the idea that polyphenols can act on both oxidative and inflammatory pathways and directly on gene networks that control osteoblast and osteoclast activity (Ameen et al., 2020).
Beyond bone mass, polyphenols may also contribute to joint health. Osteoarthritis is characterized by progressive degeneration of articular cartilage, subchondral bone remodeling, and synovial inflammation, processes in which oxidative stress and pro-inflammatory cytokines play central roles. Experimental and translational studies have shown that different polyphenolic compounds, including flavonoids and stilbenes, can reduce the production of inflammatory mediators, downregulate matrix-degrading enzymes, and mitigate oxidative damage in chondrocytes and synovial cells, ultimately preserving cartilage matrix and improving functional outcomes in osteoarthritis models (Ansari et al., 2020; Sirše, 2022). Together, these findings suggest that polyphenols may exert osteoprotective and chondroprotective effects by acting on shared molecular pathways that link inflammation, redox imbalance, and tissue remodeling in bone and joint structures.
5 Molecular and epigenetic mechanisms of polyphenols in sarcopenia
5.1 Quercetin and resveratrol in mTOR/AMPK/NF-κB pathways
The Mechanistic Target of Rapamycin (mTOR), Nuclear Factor Kappa-light-chain-enhancer of activated B cells (NF-κB), and AMP-activated protein kinase (AMPK) signaling pathways are interconnected; dysregulation of these pathways contributes to age-related muscle atrophy, whereas their appropriate modulation by exercise supports muscle mass maintenance and may help prevent sarcopenia (Li et al., 1998; Cai et al., 2004; Zeng et al., 2020; Tang et al., 2019). mTOR hyperactivity can inhibit autophagy, while NF-kB activation induces inflammation and protein degradation (Cai et al., 2004; Castets et al., 2013; Li and Reid, 2000). mTOR and NF-kB act synergistically in muscle degeneration, and this action creates a vicious cycle that accelerates muscle loss during aging (Cai et al., 2004; Tang et al., 2019; Lee and Goldberg, 2015).
AMPK activity counteracts the negative effects of mTOR and NF-kB (Wang et al., 2020). When activated by polyphenols, it inhibits NF-kB–induced inflammation and promotes mitochondrial regeneration, supporting autophagy and delaying sarcopenia progression (Don et al., 2022). Another key point about polyphenols is that their consumption directly acts on gene expression through epigenetic mechanisms, including DNA methylation, histone acetylation/deacetylation, and regulation of non-coding RNAs (Číž et al., 2020), thereby influencing genes related to autophagy, mitochondrial biogenesis, and inflammatory responses (Abdul et al., 2017; Ayissi et al., 2014). These epigenetic effects resulting from the consumption of polyphenols not only regulate cell proliferation and the stress response but also manage to amplify mechanisms related to the regeneration and preservation of muscle mass, mitigating the effects of sarcopenia (Russo et al., 2017).
Quercetin is a flavonoid present in several easily accessible foods in diets, the most common foods being apples, onions, grapes, green tea and berries (Guven et al., 2019). Its consumption, when associated with signaling pathways and muscle health, presents several benefits for the aging process. Resveratrol is one of the most studied polyphenols for presenting beneficial effects on aging and general health (Galiniak et al., 2019).
Resveratrol and quercetin have synergistic effects and when used together, they show a positive effect in the modulation of muscle health (Rayalam et al., 2011). When combined these compounds can simultaneously activate the AMPK e Sirt1 pathways, while negatively regulating mTOR and NF–kB signaling (Giovannini and Bianchi, 2017). The combined effects are particularly useful for preserving muscle health during aging, with the maintenance of muscle mass (Pan et al., 2025). In the case of resveratrol in moderate doses (∼24 mg/kg of body weight), it already has positive actions in influencing cell signaling (Shaito et al., 2020). Protective functions on muscle health are caused by the consumption of resveratrol and quercetin (Salucci and Falcieri, 2020).
These polyphenols act on muscle health by negatively regulating the mTOR pathway, promoting autophagy, increasing mitochondrial biogenesis and reducing inflammation (Lin et al., 2024). These benefits have a positive influence on the aging process and preservation of muscle mass, making resveratrol a promising ally for maintaining muscle function, preventing sarcopenia and improving metabolic health (Ispoglou et al., 2023; Micheli et al., 2023).
When we turn our attention to resveratrol and quercetin in the activation of NF-kB, the literature shows an inhibition in the activation of NF-Kb in several experimental models (Das et al., 2022; Farkhondeh et al., 2020; Yang et al., 2022), which leads to a reduction in the production of pro-inflammatory cytokines such as TNF-α, IL-6 and IL-8 (Palacz-Wrobel et al., 2017; Bisht et al., 2010). Reducing inflammation by inhibiting NF-Kb using resveratrol helps protect muscles from chronic damage and age-related muscle atrophy, maintaining the integrity of muscle cells and promoting muscle regeneration (Pan et al., 2025; Nosaka et al., 2024).
Associated with the AMPK pathway, resveratrol and quercetin help play a crucial role in regulating cellular metabolism, improving mitochondrial function (Wang M. et al., 2021). This process is important for muscle health, since mitochondria are essential for supplying energy to muscle cells during the aging process. Another benefit of resveratrol for signaling pathways is the increased expression of PGC-1α, a key regulator of mitochondrial biogenesis, promoting greater ATP production, which positively favors muscle endurance and recovery, especially when focused on aging (Gurd, 2011; Lagouge et al., 2006).
5.2 Polyphenols in inflammaging and oxidative stress
When lifestyle patterns cause persistent activation of NF-kB, systemic inflammation arises (Bosma-den Boer et al., 2012; Kannan et al., 2025; Klimczak and Śliwińska, 2024) promoting cellular dysfunction and impairing muscle regeneration (Londhe and Guttridge, 2015; Chazaud, 2016). Polyphenols such as resveratrol, quercetin and curcumin have potent anti-inflammatory properties, and when consumed, they are capable of modulating levels of NF-kB activation, alleviating the expression of pro-inflammatory cytokines (such as TNF-α, IL-6 and IL-1β) (Jantan et al., 2021).
This process helps to reduce chronic inflammation, preserving muscle function and preventing the process of sarcopenia (Dalle et al., 2017; Jensen, 2008). Another positive aspect of these polyphenolic compounds is that they modulate the production of reactive oxygen species (ROS), significantly reducing the oxidative stress generated by inflammation, minimizing the cellular damage caused by inflammation (Rudrapal et al., 2022; Zhang and Tsao, 2016; Mileo et al., 2016).
Oxidative stress occurs when there is an imbalance between the production of free radicals and the capacity to neutralize them through endogenous antioxidant systems (Hassan et al., 2024). Oxidative stress contributes detrimentally to cellular damage, including muscle damage, impairing mitochondrial function and accelerating the muscle aging process (Chen et al., 2023; Xu and Wen, 2023). Mitochondrial function plays an important role in maintaining muscle health, especially in older adults (Chen et al., 2023; Sligar et al., 2022).
Mitochondria are responsible for the production of cellular energy, essential for muscle contraction and cell regeneration (Casanova et al., 2023). Polyphenols such as resveratrol and quercetin have actions in the body to increase mitochondrial biogenesis, a process in which new mitochondria are formed, improving the energy function of muscle cells (Chodari et al., 2021; Yadav et al., 2022).
Polyphenols such as epigallocatechin gallate, resveratrol and curcumin have powerful antioxidant properties that can neutralize free radicals, increasing the activity of antioxidant enzymes such as superoxide dismutase, catalase and glutathione peroxidase, which act to protect muscle cells against oxidative damage (Rudrapal et al., 2022; Jena et al., 2023).
5.3 Epigenetic regulation of muscle health by polyphenols
Epigenetic mechanisms including DNA methylation, histone modifications, and non-coding RNAs play a central role in the regulation of muscle plasticity, repair, and aging. These processes are dynamically influenced by environmental stimuli such as nutrition and exercise, and accumulating evidence highlights dietary polyphenols as potent modulators of the epigenome. Through their interaction with epigenetic enzymes and signaling pathways, polyphenols may contribute to the preservation of skeletal muscle mass and function during aging, offering new avenues for the prevention and management of sarcopenia.
One of the most widely studied mechanisms is the modulation of DNA methylation. Polyphenols such as epigallocatechin gallate (EGCG), quercetin, and curcumin can influence the activity of DNA methyltransferases (DNMTs), thereby reversing aberrant methylation patterns associated with aging and muscle atrophy. By restoring appropriate gene expression profiles, these compounds may enhance mitochondrial biogenesis, antioxidant defense, and anabolic pathways essential for muscle maintenance (Ullah et al., 2020).
Importantly, evidence also shows that several polyphenols including EGCG, quercetin, curcumin and resveratrol modulate chromatin-remodeling enzymes such as DNMTs, HATs and HDACs, reinforcing their broad epigenetic impact beyond antioxidant and anti-inflammatory mechanisms (Ayissi et al., 2014).
In addition, polyphenols affect histone modifications, which regulate chromatin accessibility and transcriptional activity. Resveratrol, for example, is known to activate SIRT1, a class III histone deacetylase that orchestrates cellular stress responses, energy metabolism, and mitochondrial function. SIRT1 activation contributes to the suppression of NF-κB–mediated inflammation, enhancement of autophagy, and improvement of muscle endurance, linking resveratrol directly to pathways relevant for sarcopenia (Ayissi et al., 2014). Similarly, curcumin and quercetin modulate histone acetyltransferases and deacetylases, contributing to improved redox balance and reduced inflammaging (Cao et al., 2025).
Another critical layer of regulation involves microRNAs (miRNAs), which fine-tune gene expression post-transcriptionally. Polyphenols have been shown to modulate miRNAs involved in oxidative stress responses, insulin sensitivity, and myogenic differentiation. For instance, EGCG influences the expression of miR-133 and miR-206, both implicated in muscle regeneration and hypertrophy (Ullah et al., 2020; Arora et al., 2020). This epigenetic modulation of miRNAs is also supported by broader evidence showing polyphenol-induced changes in non-coding RNA networks (Rajendran et al., 2022).
Collectively, these findings underscore that polyphenols exert multi-layered epigenetic regulation, targeting DNA methylation, histone remodeling, and non-coding RNAs. This integrated control aligns with the geroscience perspective, where modulation of aging hallmarks such as mitochondrial dysfunction, loss of proteostasis, and cellular senescence can delay or attenuate sarcopenia. Thus, dietary polyphenols emerge not only as antioxidants or anti-inflammatory agents, but also as epigenetic regulators, positioning them as promising adjuncts in strategies to maintain muscle health during aging (Ayissi et al., 2014; Ullah et al., 2020; Cao et al., 2025; Arora et al., 2020).
6 Experimental evidence: polyphenols and sarcopenia
Clinical studies show that the effects of dietary polyphenols on sarcopenia are promising but heterogenous, depending on multiple factors such as polyphenols, type, dosage, intervention duration, participant characteristic, and diagnostic criteria.
The most frequently studied polyphenols were catechins (including epicatechin), isoflavones, and marine-derived oligomeric polyphenols. Catechins and Epicatechins (Tokuda and Mori, 2023; Mafi et al., 2019; Kim et al., 2013; Munguia et al., 2019) were generally associated with improved muscle strength and physical performance. For instance, Kim et al. reported enhancements in grip and knee extension strength, as well as walking speeds, after administering 540 mg of catechins for 3 months. Mafi et al., using 1 mg/kg/day of epicatechin, observed significant gains in leg and chest press strength, alongside improved performance in the timed up and go test. Regarding isoflavones, Aubertin-Leheudre et al. (Aubertin-Leheudre et al., 2007) demonstrated improvement in the muscle mass index after 24 weeks with a dosage of 70 mg/day. Chang et al. (Chang et al., 2023) reported positive effects on both muscle mass and function over 10 weeks with 87.2 mg/day, suggesting a dose-duration dependency. Marine-Derived Polyphenols were less commonly studied but indicated potential improvements in muscle strength and balance-related performance outcomes, although the sample size was limited (n = 20) (Kwon et al., 2021).
Sarcopenia was assessed via different diagnostic criteria and outcome measures, leading to heterogeneity in findings. Diagnostic criteria included EWGSOP2 (2019), Asian Working Group for Sarcopenia (AWGS), Foundation for the National Institutes of Health (FNIH), and other author-defined criteria. This variation affects comparability, as cutoff values and component emphasis (e.g., grip strength vs. gait speed) differ. Muscle mass was usually measured using appendicular skeletal muscle mass index, appendicular muscle mass index, or total muscle mass (Kim et al., 2013; Yasunobu and Mori, 2021). Most studies reported improvements or maintenance in muscle mass, particularly with longer intervention durations (>12 weeks). Muscle strength was commonly evaluated through grip strength (Tokuda and Mori, 2023; Kim et al., 2013; Kwon et al., 2021) and leg/chest press (Mafi et al., 2019). Physical performance was measured by various tests (e.g., 5-m walk, timed up and go, gait speed) (Mafi et al., 2019; Yasunobu and Mori, 2021).
Three studies (Tokuda and Mori, 2023; Mafi et al., 2019; Kim et al., 2017) included resistance or multicomponent exercise regimens, revealing that the combination of polyphenols with physical activity led to greater improvements in muscle function and performance. This supports the notion of a synergistic effect between dietary polyphenols and exercise, possibly due to enhanced muscle protein synthesis and anti-inflammatory pathways.
Although these clinical trials rarely investigated epigenetic endpoints, the observed functional benefits may reflect underlying mechanisms such as SIRT1 activation, DNMT inhibition, or microRNA regulation, which have been described in preclinical models of muscle aging. From a geroscience perspective, this suggests that polyphenols not only act as antioxidants or anti-inflammatory agents but also modulate key hallmarks of aging including mitochondrial dysfunction, chronic inflammation, and cellular senescence that drive sarcopenia progression. Future clinical studies should therefore incorporate biomarkers of aging, such as DNA methylation clocks and other epigenetic signatures, to better connect functional outcomes with molecular mechanisms (Figure 2).
Figure 2. Polyphenols, molecular pathways, and epigenetic mechanisms involved in muscle health. Note - Polyphenols such as resveratrol, EGCG, curcumin, and quercetin modulate metabolic pathways (AMPK, mTOR, NF-κB), promoting mitochondrial biogenesis, autophagy, and reduced inflammation. These actions converge with epigenetic mechanisms including DNA demethylation, histone/SIRT1 regulation, and microRNAs (e.g., miR-133, miR-206) to support mitochondrial function, muscle regeneration, and the preservation of muscle mass and strength. Collectively, these effects contribute to delaying or preventing sarcopenia.
6.1 Epicatechin as a modulator of myostatin signaling
Myostatin, a member of the TGF-β superfamily, is one of the most potent negative regulators of skeletal muscle growth. Its overexpression is closely associated with reduced protein synthesis, decreased satellite cell activation and enhanced proteolytic activity, contributing directly to age-related muscle atrophy. Elevated myostatin levels have been consistently reported in older adults with low muscle mass and impaired functional performance, reinforcing its relevance as a molecular hallmark of sarcopenia (Consitt and Clark, 2018).
Among dietary polyphenols, epicatechin has emerged as a promising candidate capable of modulating this pathway. Experimental work in aging mice demonstrated that epicatechin treatment reduces myostatin expression while increasing follistatin, a key physiological antagonist that promotes muscle growth. These changes were accompanied by increases in myogenic regulatory factors such as Myf5, MyoD and myogenin, suggesting enhanced regenerative potential in aged muscle (Gutierrez-Salmean et al. 2014).
In translational research, short-term administration of epicatechin in humans has produced similar patterns. A randomized trial in sarcopenic older adults found that resistance training combined with epicatechin supplementation improved muscle strength and was associated with favorable adjustments in circulating myostatin and follistatin levels (Mafi et al., 2019). Complementary evidence from clinical studies in patients with Becker muscular dystrophy also demonstrates mitochondrial adaptations and increases in follistatin following epicatechin intake, supporting the hypothesis that this compound influences molecular circuits relevant for muscle maintenance and repair (McDonald et al., 2021).
Beyond its effects on myostatin signaling, epicatechin also contributes to improved mitochondrial biogenesis and redox homeostasis, processes that decline with aging and amplify muscle atrophy. These effects are mediated through pathways such as PGC-1α activation and improved mitochondrial function, which collectively enhance muscle bioenergetics and regenerative potential (McDonald et al., 2021; Moreno-Ulloa et al., 2018).
This molecular profile positions epicatechin as a multi-target modulator capable of influencing both catabolic and anabolic signals in skeletal muscle. Its impact on myostatin–follistatin balance integrates seamlessly with the broader mechanisms discussed in this section, reinforcing the concept that polyphenols can affect muscle health not only through antioxidant or anti-inflammatory actions but also by directly modulating signaling networks central to sarcopenia.
7 Challenges and limitations in studies on polyphenols and sarcopenia
Although the emerging evidence points toward beneficial effects of dietary polyphenols on sarcopenia-related outcomes, some challenges and limitations hinder the ability to draw firm conclusions. These issues are largely centered around methodological variability, differences in polyphenol type and dosage, inconsistencies in outcome measurement, and a lack of rigorous long-term clinical trials.
One of the foremost challenges is the heterogeneity of polyphenolic compounds used across studies. The term “polyphenols” encompasses a vast group of bioactive compounds, including flavonoids (e.g., catechins, epicatechins, isoflavones), phenolic acids, and oligomeric polyphenols of marine origin. Some interventions used isolated compounds (e.g., pure epicatechin or isoflavones), while others employed complex mixtures, such as cocoa beverages rich in multiple flavonoids (Munguia et al., 2019). The mechanisms of action and bioavailability profiles differ substantially between compounds. For example, catechins are known for their antioxidant and mitochondrial-enhancing properties, while isoflavones have estrogenic effects, which may have sex-specific implications for muscle metabolism. The standardization and characterization of the supplements are often lacking, making it difficult to replicate findings or compare across studies. The dosage of polyphenols administered varied widely, from as little as 25 mg of epicatechin (Munguia et al., 2019) to 540 mg of catechins (Tokuda and Mori, 2023; Kim et al., 2013). This variation complicates dose-response assessments and raises questions about the minimal effective dose for clinical benefit.
Some studies used body weight-adjusted dosing (e.g., Mafi et al., 1 mg/kg/day of epicatechin), while others applied fixed daily amounts, regardless of inter-individual differences in metabolism or absorption. The intervention durations ranged from 4 to 24 weeks, often too short to detect long-term changes in muscle mass or prevent functional decline. Given the chronic and progressive nature of sarcopenia, short-term studies may only reflect transient or early-stage changes rather than durable outcomes.
Many studies were limited by small sample sizes, such as those conducted by Aubertin-Leheudre et al. (n = 18) (Aubertin-Leheudre et al., 2007) and Kwon et al. (n = 20) (Kwon et al., 2021), which reduce statistical power and increase the risk of Type II errors. In addition, there was marked heterogeneity in the diagnostic criteria used to define sarcopenia, including the EWGSOP, the AWGS, and the FNIH criteria. Not all studies assessed all three sarcopenia-related domains, muscle mass, muscle strength, and physical performance, which may lead to incomplete evaluations of intervention efficacy. Furthermore, some trials lacked methodological rigor, such as the absence of placebo controls or randomization, which increases susceptibility to bias. For example, the study by Tokuda et al. employed a single-arm design, limiting the internal validity of the findings.
Another major limitation arises from the inclusion of co-interventions that confound the interpretation of results. Several trials combined polyphenol supplementation with exercise training or amino acid co-supplementation, such as those by Tokuda (Tokuda and Mori, 2023) et al. and Mafi et al. (Mafi et al., 2019). While these multi-component approaches may better reflect real-world clinical practice, they complicate efforts to attribute observed benefits specifically to polyphenols. Additionally, many studies did not adequately control for potential confounding variables such as dietary intake, concurrent medication use, or the presence of comorbid conditions, all of which can influence muscle metabolism and interact with polyphenol absorption and bioactivity.
Given these limitations, there is a clear need for more rigorously designed, well-controlled, and long-term randomized placebo-controlled clinical trials to validate the real-world effects of polyphenols in the prevention and treatment of sarcopenia.
8 Geroscience perspectives and therapeutic implications
Taken together, the integration of tailored strategies based on polyphenols with structured physical exercise emerges as a promising dual-intervention approach to prevent or attenuate sarcopenia and its associated health burdens in aging populations. By targeting shared molecular pathways involved in inflammation, oxidative stress, mitochondrial dysfunction, and cellular senescence, polyphenols and exercise may have complementary effects that enhance muscle maintenance and functional capacity. By targeting inflammation, oxidative stress, mitochondrial dysfunction, and senescence, polyphenols and exercise may complement each other to preserve muscle and function.
Notably, the personalization of these strategies, considering an individual’s metabolic profile, dietary habits, and physical capacity, may enhance adherence and intervention therapeutic effectiveness. In this sense, future randomized controlled studies are warranted to confirm benefits with a focus on prevention and restoring muscle health. However, some steps are required first, as it is still necessary to determine an optimal dosage and delivery of polyphenols and establish clinically relevant biomarkers of response. Such advances could help solidify the support and role of lifestyle interventions as essential tools in combating age-related muscle decline and promoting healthy longevity.
Despite encouraging previously discussed evidence, the transition toward individualized prescriptions of polyphenol-based nutritional support and exercise interventions remains an important gap in sarcopenia research. Interindividual variability in gut microbiota composition, genetic polymorphisms, and especially epigenetic markers such as DNA methylation clocks, histone signatures, and microRNA profiles, significantly influences the bioavailability and metabolic response to polyphenols, as well as the efficacy of exercise regimens. Understanding these variables could guide the development of precision interventions to maximize therapeutic outcomes. For instance, stratifying individuals based on their ability to metabolize specific polyphenols or their responsiveness to physical training could improve intervention targeting. Further research should consider integrating omics technologies, such as nutrigenomics, metabolomics, and transcriptomics, into clinical practice will be crucial to identify biomarkers that predict treatment efficacy and guide the customization of interventions. Future trials should therefore prioritize stratified study designs and explore adaptive interventions that respond to an individual’s changing physiological profile across the aging trajectory.
9 Conclusion
This review highlights growing evidence that polyphenols modulate muscle aging through antioxidants, anti-inflammatory, mitochondrial, and epigenetic mechanisms. These compounds show promise as adjunct strategies for the prevention and management of sarcopenia, particularly when combined with structured physical exercise.
Despite encouraging findings, important gaps remain regarding dosing, bioavailability, interindividual variability, and long-term efficacy. Future trials should integrate biomarker validation, including epigenetic signatures, to advance precision nutrition approaches. Polyphenols within the geroscience framework underscores their potential as both modulators of aging hallmarks and regulators of muscle health, opening new avenues for translational strategies against sarcopenia.
Author contributions
GSR: Conceptualization, Investigation, Methodology, Project administration, Visualization, Writing – original draft, Writing – review and editing. LSLS: Conceptualization, Investigation, Methodology, Project administration, Visualization, Writing – original draft, Writing – review and editing. ACSS: Conceptualization, Investigation, Methodology, Project administration, Visualization, Writing – original draft, Writing – review and editing. JB: Conceptualization, Investigation, Methodology, Project administration, Writing – original draft, Writing – review and editing. GFA: Conceptualization, Investigation, Methodology, Visualization, Writing – original draft, Writing – review and editing. GUO: Conceptualization, Methodology, Validation, Writing – original draft, Writing – review and editing. ECF: Conceptualization, Methodology, Project administration, Validation, Writing – original draft, Writing – review and editing. CRBJ: Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Writing – original draft, Writing – review and editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This study was financed in by the São Paulo Research Foundation (FAPESP; grant n° 23/08249-0) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior–Brasil (CAPES) – Finance Code 001.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Abdul, Q. A., Yu, B. P., Chung, H. Y., Jung, H. A., and Choi, J. S. (2017). Epigenetic modifications of gene expression by lifestyle and environment. Arch. Pharm. Res. 40 (11), 1219–1237. doi:10.1007/s12272-017-0973-3
Aghababaei, F., and Hadidi, M. (2023). Recent advances in potential health benefits of quercetin. Pharm. Basel Switz. 16 (7), 1020. doi:10.3390/ph16071020
Ameen, O., Yassien, R. I., and Naguib, Y. M. (2020). Activation of FoxO1/SIRT1/RANKL/OPG pathway may underlie the therapeutic effects of resveratrol on aging-dependent male osteoporosis. BMC Musculoskelet. Disord. 21 (1), 375. doi:10.1186/s12891-020-03389-w
Ansari, M. Y., Ahmad, N., and Haqqi, T. M. (2020). Oxidative stress and inflammation in osteoarthritis pathogenesis: role of polyphenols. Biomed. Pharmacother. 129, 110452. doi:10.1016/j.biopha.2020.110452
Antoun, E., Garratt, E. S., Taddei, A., Burton, M. A., Barton, S. J., Titcombe, P., et al. (2022). Epigenome-wide association study of sarcopenia: findings from the hertfordshire sarcopenia study (HSS). J. Cachexia Sarcopenia Muscle 13 (1), 240–253. doi:10.1002/jcsm.12876
Arfaoui, L. (2021). Dietary plant polyphenols: effects of food processing on their content and bioavailability. Molecules 26 (10), 2959. doi:10.3390/molecules26102959
Arora, I., Sharma, M., Sun, L. Y., and Tollefsbol, T. O. (2020). The epigenetic link between polyphenols, aging and age-related diseases. Genes 11 (9), 1094. doi:10.3390/genes11091094
Aubertin-Leheudre, M., Lord, C., Khalil, A., and Dionne, I. J. (2007). Six months of isoflavone supplement increases fat-free mass in obese–sarcopenic postmenopausal women: a randomized double-blind controlled trial. Eur. J. Clin. Nutr. 61 (12), 1442–1444. doi:10.1038/sj.ejcn.1602695
Ayissi, V. B. O., Ebrahimi, A., and Schluesenner, H. (2014). Epigenetic effects of natural polyphenols: a focus on SIRT1-mediated mechanisms. Mol. Nutr. Food Res. 58 (1), 22–32. doi:10.1002/mnfr.201300195
Beylerli, O., Beilerli, A., Shumadalova, A., Wang, X., Yang, M., Sun, H., et al. (2022). Therapeutic effect of natural polyphenols against glioblastoma. Front. Cell Dev. Biol. 10, 1036809. doi:10.3389/fcell.2022.1036809
Bisht, K., Wagner, K. H., and Bulmer, A. C. (2010). Curcumin, resveratrol and flavonoids as anti-inflammatory, cyto- and DNA-protective dietary compounds. Toxicology 278 (1), 88–100. doi:10.1016/j.tox.2009.11.008
Boccardi, V. (2024). Sarcopenia: a dive into metabolism to promote a multimodal, preventive, and regenerative approach. Mech. Ageing Dev. 219, 111941. doi:10.1016/j.mad.2024.111941
Bogucka, D., Wajda, A., Stypińska, B., Radkowski, M. J., Targowski, T., Modzelewska, E., et al. (2025). Epigenetic factors and inflammaging: FOXO3A as a potential biomarker of sarcopenia and upregulation of DNMT3A and SIRT3 in older adults. Front. Immunol. 16, 1467308. doi:10.3389/fimmu.2025.1467308
Boros, K., and Freemont, T. (2017). Physiology of ageing of the musculoskeletal system. Best. Pract. Res. Clin. Rheumatol. 31 (2), 203–217. doi:10.1016/j.berh.2017.09.003
Borzuola, R., Giombini, A., Torre, G., Campi, S., Albo, E., Bravi, M., et al. (2020). Central and peripheral neuromuscular adaptations to ageing. J. Clin. Med. 9 (3), 741. doi:10.3390/jcm9030741
Bosma-den Boer, M. M., Van Wetten, M. L., and Pruimboom, L. (2012). Chronic inflammatory diseases are stimulated by current lifestyle: how diet, stress levels and medication prevent our body from recovering. Nutr. Metab. 9 (1), 32. doi:10.1186/1743-7075-9-32
Cai, D., Frantz, J. D., Tawa, N. E., Melendez, P. A., Oh, B. C., Lidov, H. G. W., et al. (2004). IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell 119 (2), 285–298. doi:10.1016/j.cell.2004.09.027
Cao, X., Cui, X., and Badehnoosh, B. (2025). Epigenetic modulation and brain function in parkinson’s disease: the role of exercise alone or combined with polyphenols. Food Sci. Nutr. 13 (8), e70696. doi:10.1002/fsn3.70696
Capasso, L., De Masi, L., Sirignano, C., Maresca, V., Basile, A., Nebbioso, A., et al. (2025). Epigallocatechin gallate (EGCG): pharmacological properties, biological activities and therapeutic potential. Mol. Basel Switz. 30 (3), 654. doi:10.3390/molecules30030654
Casanova, A., Wevers, A., Navarro-Ledesma, S., and Pruimboom, L. (2023). Mitochondria: it is all about energy. Front. Physiol. 14, 1114231. doi:10.3389/fphys.2023.1114231
Castets, P., Lin, S., Rion, N., Di Fulvio, S., Romanino, K., Guridi, M., et al. (2013). Sustained activation of mTORC1 in skeletal muscle inhibits constitutive and starvation-induced autophagy and causes a severe, late-onset myopathy. Cell Metab. 17 (5), 731–744. doi:10.1016/j.cmet.2013.03.015
Chang, S. S., Chen, L. H., Huang, K. C., Huang, S. W., Chang, C. C., Liao, K. W., et al. (2023). Plant-based polyphenol rich protein supplementation attenuated skeletal muscle loss and lowered the LDL level via gut microbiota remodeling in Taiwan’s community-dwelling elderly. Food Funct. 14 (20), 9407–9418. doi:10.1039/d3fo02766j
Chazaud, B. (2016). Inflammation during skeletal muscle regeneration and tissue remodeling: application to exercise-induced muscle damage management. Immunol. Cell Biol. 94 (2), 140–145. doi:10.1038/icb.2015.97
Chen, Y., and Wu, J. (2025). Aging-related sarcopenia: metabolic characteristics and therapeutic strategies. Aging Dis. 16 (2), 1003–1022. doi:10.14336/AD.2024.0407
Chen, X., Ji, Y., Liu, R., Zhu, X., Wang, K., Yang, X., et al. (2023). Mitochondrial dysfunction: roles in skeletal muscle atrophy. J. Transl. Med. 21 (1), 503. doi:10.1186/s12967-023-04369-z
Chinvattanachot, G., Rivas, D., and Duque, G. (2024). Mechanisms of muscle cells alterations and regeneration decline during aging. Ageing Res. Rev. 102, 102589. doi:10.1016/j.arr.2024.102589
Chodari, L., Dilsiz Aytemir, M., Vahedi, P., Alipour, M., Vahed, S. Z., Khatibi, S. M. H., et al. (2021). “Targeting mitochondrial biogenesis with polyphenol compounds. Oxid. Med. Cell Longev. 2021 4946711. doi:10.1155/2021/4946711
Ciupei, D., Colişar, A., Leopold, L., Stănilă, A., and Diaconeasa, Z. M. (2024). Polyphenols: from classification to therapeutic potential and bioavailability. Foods 13 (24), 4131. doi:10.3390/foods13244131
Číž, M., Dvořáková, A., Skočková, V., and Kubala, L. (2020). The role of dietary phenolic compounds in epigenetic modulation involved in inflammatory processes. Antioxidants 9 (8), 691. doi:10.3390/antiox9080691
Consitt, L. A., and Clark, B. C. (2018). The vicious cycle of myostatin signaling in sarcopenic obesity: myostatin role in skeletal muscle growth, insulin signaling and implications for clinical trials. J. Frailty Aging. 7 (1), 21–27. doi:10.14283/jfa.2017.33
Daily, J. W., and Park, S. (2022). Sarcopenia is a cause and consequence of metabolic dysregulation in aging humans: effects of gut dysbiosis, glucose dysregulation, diet and lifestyle. Cells 11 (3), 338. doi:10.3390/cells11030338
Dalle, S., Rossmeislova, L., and Koppo, K. (2017). The role of inflammation in age-related sarcopenia. Front. Physiol. 8, 1045. doi:10.3389/fphys.2017.01045
Das, R., Mehta, D. K., and Dhanawat, M. (2022). Medicinal plants in cancer treatment: contribution of nuclear Factor- kappa B (NF-kB) inhibitors. Mini-Rev Med. Chem. 22 (15), 1938–1962. doi:10.2174/1389557522666220307170126
Donati Zeppa, S., Agostini, D., Ferrini, F., Gervasi, M., Barbieri, E., Bartolacci, A., et al. (2022). Interventions on gut microbiota for healthy aging. Cells 12 (1), 34. doi:10.3390/cells12010034
Evans, W. J., and Lexell, J. (1995). Human aging, muscle mass, and fiber type composition. J. Gerontol. A Biol. Sci. Med. Sci. 50A (Special), 11–16. doi:10.1093/gerona/50a.special_issue.11
Fagbohun, O. F., Gillies, C. R., Murphy, K. P. J., and Rupasinghe, H. P. V. (2023). Role of antioxidant vitamins and other micronutrients on regulations of specific genes and signaling pathways in the prevention and treatment of cancer. Int. J. Mol. Sci. 24 (7), 6092. doi:10.3390/ijms24076092
Farkhondeh, T., Folgado, S. L., Pourbagher-Shahri, A. M., Ashrafizadeh, M., and Samarghandian, S. (2020). The therapeutic effect of resveratrol: focusing on the Nrf2 signaling pathway. Biomed. Pharmacother. 127, 110234. doi:10.1016/j.biopha.2020.110234
Galiniak, S., Aebisher, D., and Bartusik-Aebisher, D. (2019). Health benefits of resveratrol administration. Acta Biochim. Pol. 66 (1), 13–21. doi:10.18388/abp.2018_2749
Giovannini, L., and Bianchi, S. (2017). Role of nutraceutical SIRT1 modulators in AMPK and mTOR pathway: evidence of a synergistic effect. Nutrition 34, 82–96. doi:10.1016/j.nut.2016.09.008
Goldring, S. R., and Goldring, M. B. (2016). Changes in the osteochondral unit during osteoarthritis: structure, function and cartilage–bone crosstalk. Nat. Rev. Rheumatol. 12 (11), 632–644. doi:10.1038/nrrheum.2016.148
González, S., Cuervo, A., and Lasheras, C. (2013). Polyphenol intake in elderly people is associated with lipid oxidative damage. J. Am. Coll. Nutr. 32 (6), 384–390. doi:10.1080/07315724.2013.827022
Gurd, B. J. (2011). Deacetylation of PGC-1α by SIRT1: importance for skeletal muscle function and exercise-induced mitochondrial biogenesis. Appl. Physiol. Nutr. Metab. 36 (5), 589–597. doi:10.1139/h11-070
Gutierrez-Salmean, G., Ciaraldi, T. P., Nogueira, L., Barboza, J., Taub, P. R., Hogan, M. C., et al. (2014). Effects of epicatechin on molecular modulators of skeletal muscle growth and differentiation. J. Nutr. Biochem. 25 (1), 91–94. doi:10.1016/j.jnutbio.2013.09.007
Guven, H., Arici, A., and Simsek, O. (2019). Flavonoids in our foods: a short review. J. Basic Clin. Health Sci. doi:10.30621/jbachs.2019.555
Hajam, Y. A., Rani, R., Ganie, S. Y., Sheikh, T. A., Javaid, D., Qadri, S. S., et al. (2022). Oxidative stress in human pathology and aging: molecular mechanisms and perspectives. Cells 11 (3), 552. doi:10.3390/cells11030552
Hassan, H. A., Ahmed, H. S., and Hassan, D. F. (2024). Free radicals and oxidative stress: mechanisms and therapeutic targets. Hum. Antibodies 32 (4), 151–167. doi:10.3233/HAB-240011
He, L., Khanal, P., Morse, C. I., Williams, A., and Thomis, M. (2020). Associations of combined genetic and epigenetic scores with muscle size and muscle strength: a pilot study in older women. J. Cachexia Sarcopenia Muscle 11 (6), 1548–1561. doi:10.1002/jcsm.12585
He, N., Zhang, Y., Zhang, L., Zhang, S., and Ye, H. (2021). Relationship between sarcopenia and cardiovascular diseases in the elderly: an overview. Front. Cardiovasc Med. 8, 743710. doi:10.3389/fcvm.2021.743710
Hu, F. B. (2024). Diet strategies for promoting healthy aging and longevity: an epidemiological perspective. J. Intern Med. 295 (4), 508–531. doi:10.1111/joim.13728
Hu, J., Wang, Y., Ji, X., Zhang, Y., Li, K., and Huang, F. (2024). Non-pharmacological strategies for managing sarcopenia in chronic diseases. Clin. Interv. Aging 19, 827–841. doi:10.2147/CIA.S455736
Ispoglou, T., Wilson, O., McCullough, D., Aldrich, L., Ferentinos, P., Lyall, G., et al. (2023). A narrative review of non-pharmacological strategies for managing sarcopenia in older adults with cardiovascular and metabolic diseases. Biology 12 (7), 892. doi:10.3390/biology12070892
Izzo, A., Massimino, E., Riccardi, G., and Della Pepa, G. (2021). A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors. Nutrients 13 (1), 183. doi:10.3390/nu13010183
Jantan, I., Haque, M. A., Arshad, L., Harikrishnan, H., Septama, A. W., and Mohamed-Hussein, Z. A. (2021). Dietary polyphenols suppress chronic inflammation by modulation of multiple inflammation-associated cell signaling pathways. J. Nutr. Biochem. 93, 108634. doi:10.1016/j.jnutbio.2021.108634
Jena, A. B., Samal, R. R., Bhol, N. K., and Duttaroy, A. K. (2023). Cellular Red-Ox system in health and disease: the latest update. Biomed. Pharmacother. 162, 114606. doi:10.1016/j.biopha.2023.114606
Jensen, G. L. (2008). Inflammation: roles in aging and sarcopenia. J. Parenter. Enter. Nutr. 32 (6), 656–659. doi:10.1177/0148607108324585
Kannan, G., Paul, B. M., and Thangaraj, P. (2025). Stimulation, regulation, and inflammaging interventions of natural compounds on nuclear factor kappa B (NF-kB) pathway: a comprehensive review. Inflammopharmacology 33 (1), 145–162. doi:10.1007/s10787-024-01635-4
Karam, J., Bibiloni, M. D. M., and Tur, J. A. (2018). “Polyphenol estimated intake and dietary sources among older adults from mallorca island. Plos One. 13 e0191573. doi:10.1371/journal.pone.0191573
Kesh, M., and Goel, S. (2023). Polyphenols: plant-based nutraceuticals in human health. Editor M. Rudrapal (Wiley), 45–66. doi:10.1002/9781394188864.ch3
Kim, H., Suzuki, T., Saito, K., Yoshida, H., Kojima, N., Kim, M., et al. (2013). Effects of exercise and tea catechins on muscle mass, strength and walking ability in community-dwelling elderly Japanese sarcopenic women: a randomized controlled trial. Geriatr. Gerontol. Int. 13 (2), 458–465. doi:10.1111/j.1447-0594.2012.00923.x
Kim, H., Banerjee, N., Barnes, R. C., Pfent, C. M., Talcott, S. T., Dashwood, R. H., et al. (2017). Mango polyphenolics reduce inflammation in intestinal colitis-involvement of the miR-126/PI3K/AKT/mTOR axis in vitro and in vivo: mango polyphenolics suppress colitis. Mol. Carcinog. 56 (1), 197–207. doi:10.1002/mc.22484
Klimczak, S., and Śliwińska, A. (2024). Epigenetic regulation of inflammation in insulin resistance. Semin. Cell Dev. Biol. 154, 185–192. doi:10.1016/j.semcdb.2022.09.004
Kwon, I. S., Park, D. S., Shin, H. C., Seok, M. G., and Oh, J. K. (2021). Effects of marine oligomeric polyphenols on body composition and physical ability of elderly individuals with sarcopenia: a pilot study. Phys. Act. Nutr. 25 (3), 1–7. doi:10.20463/pan.2021.0014
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., et al. (2006). Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 127 (6), 1109–1122. doi:10.1016/j.cell.2006.11.013
Larsson, L., Degens, H., Li, M., Salviati, L., Lee, Y. I., Thompson, W., et al. (2019). Sarcopenia: aging-related loss of muscle mass and function. Physiol. Rev. 99 (1), 427–511. doi:10.1152/physrev.00061.2017
Lee, D., and Goldberg, A. L. (2015). Muscle wasting in fasting requires activation of NF-κB and inhibition of AKT/mechanistic target of rapamycin (mTOR) by the protein acetylase, GCN5. J. Biol. Chem. 290 (51), 30269–30279. doi:10.1074/jbc.M115.685164
Li, Y. P., and Reid, M. B. (2000). NF-κB mediates the protein loss induced by TNF-α in differentiated skeletal muscle myotubes. Am. J. Physiol-Regul Integr. Comp. Physiol. 279 (4), R1165–R1170. doi:10.1152/ajpregu.2000.279.4.R1165
Li, Y., Schwartz, R. J., Waddell, I. D., Holloway, B. R., and Reid, M. B. (1998). Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-κB activation in response to tumor necrosis factorα. FASEB J. 12 (10), 871–880. doi:10.1096/fasebj.12.10.971
Li, Y., Li, L., Li, X., Luo, B., Ye, Q., Wang, H., et al. (2022). A mechanistic review of Chinese medicine polyphenols on bone formation and resorption. Front. Pharmacol. 13, 1017538. doi:10.3389/fphar.2022.1017538
Li, X., Li, C., Zhang, W., Wang, Y., Qian, P., and Huang, H. (2023). Inflammation and aging: signaling pathways and intervention therapies. Signal Transduct. Target Ther. 8 (1), 239. doi:10.1038/s41392-023-01502-8
Li, J., Shen, Z., Lin, Y., Wang, Z., Li, M., Sun, H., et al. (2024). DNA methylation of skeletal muscle function-related secretary factors identifies FGF2 as a potential biomarker for sarcopenia. J. Cachexia Sarcopenia Muscle 15 (3), 1209–1217. doi:10.1002/jcsm.13472
Lian, R., Liu, Q., Jiang, G., Zhang, X., Tang, H., Lu, J., et al. (2024). Blood biomarkers for sarcopenia: a systematic review and meta-analysis of diagnostic test accuracy studies. Ageing Res. Rev. 93, 102148. doi:10.1016/j.arr.2023.102148
Lin, X., Liu, W., Hu, X., Liu, Z., Wang, F., and Wang, J. (2024). The role of polyphenols in modulating mitophagy: implications for therapeutic interventions. Pharmacol. Res. 207, 107324. doi:10.1016/j.phrs.2024.107324
Liu, C., Wong, P. Y., Chung, Y. L., Chow, S. K., Cheung, W. H., Law, S. W., et al. (2023). Deciphering the “obesity paradox” in the elderly: a systematic review and meta-analysis of sarcopenic obesity. Obes. Rev. 24 (2), e13534. doi:10.1111/obr.13534
Liu, D., Wang, S., Liu, S., Wang, Q., Che, X., and Wu, G. (2024). Frontiers in sarcopenia: advancements in diagnostics, molecular mechanisms, and therapeutic strategies. Mol. Asp. Med. 97, 101270. doi:10.1016/j.mam.2024.101270
Londhe, P., and Guttridge, D. C. (2015). Inflammation induced loss of skeletal muscle. Bone 80, 131–142. doi:10.1016/j.bone.2015.03.015
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., and Kroemer, G. (2023). Hallmarks of aging: an expanding universe. Cell. 186 (2), 243–278. doi:10.1016/j.cell.2022.11.001
Mafi, F., Biglari, S., Ghardashi Afousi, A., and Gaeini, A. A. (2019). Improvement in skeletal muscle strength and plasma levels of follistatin and myostatin induced by an 8-Week resistance training and epicatechin supplementation in sarcopenic older adults. J. Aging Phys. Act. 27 (3), 384–391. doi:10.1123/japa.2017-0389
McDonald, C. M., Ramirez-Sanchez, I., Oskarsson, B., Joyce, N., Aguilar, C., Nicorici, A., et al. (2021). Epicatechin induces mitochondrial biogenesis and markers of muscle regeneration in adults with becker muscular dystrophy. Muscle Nerve 63 (2), 239–249. doi:10.1002/mus.27108
Medoro, A., Scapagnini, G., and Davinelli, S. (2024). Polyphenol supplementation and sarcopenia: a systematic review and meta-analysis of clinical trials. J. Frailty Aging 13 (4), 432–440. doi:10.14283/jfa.2024.73
Menon, V. P., and Sudheer, A. R. (2007). Antioxidant and anti-inflammatory properties of curcumin. Adv. Exp. Med. Biol. 595, 105–125. doi:10.1007/978-0-387-46401-5_3
Micheli, L., Bertini, L., Bonato, A., Villanova, N., Caruso, C., Caruso, M., et al. (2023). Role of hydroxytyrosol and oleuropein in the prevention of aging and related disorders: focus on neurodegeneration, skeletal muscle dysfunction and gut microbiota. Nutrients 15 (7), 1767. doi:10.3390/nu15071767
Mileo, A. M., and Miccadei, S. (2016). Polyphenols as modulator of oxidative stress in cancer disease: new therapeutic strategies. Oxid. Med. Cell Longev. 2016 6475624. doi:10.1155/2016/6475624
Miranda, A. M., Steluti, J., Fisberg, R. M., and Marchioni, D. M. (2016). Dietary intake and food contributors of polyphenols in adults and elderly adults of Sao Paulo: a population-based study. Br. J. Nutr. 115 (6), 1061–1070. doi:10.1017/S0007114515005061
Moreno-Ulloa, A., Miranda-Cervantes, A., Licea-Navarro, A., Mansour, C., Beltrán-Partida, E., Donis-Maturano, L., et al. (2018). Epicatechin stimulates mitochondrial biogenesis and cell growth in C2C12 myotubes via the G-protein coupled estrogen receptor. Eur. J. Pharmacol. 822, 95–107. doi:10.1016/j.ejphar.2018.01.014
Munguia, L., Rubio-Gayosso, I., Ramirez-Sanchez, I., Ortiz, A., Hidalgo, I., Gonzalez, C., et al. (2019). High flavonoid cocoa supplement ameliorates plasma oxidative stress and inflammation levels while improving mobility and quality of life in older subjects: a double-blind randomized clinical trial. J. Gerontol. Ser. 74 (10), 1620–1627. doi:10.1093/gerona/glz107
Musial, C., Kuban-Jankowska, A., and Gorska-Ponikowska, M. (2020). Beneficial properties of green tea catechins. Int. J. Mol. Sci. 21 (5), 1744. doi:10.3390/ijms21051744
Napolitano, G., Fasciolo, G., and Venditti, P. (2021). Mitochondrial management of reactive oxygen species. Antioxidants 10 (11), 1824. doi:10.3390/antiox10111824
Nosaka, K., Ooi, C. H., Nosaka, K., Rathakrishnan, V., Chan, S. Y., and Karim, N. K. A. (2024). Effects of resveratrol supplementation on delayed onset muscle soreness and muscle recovery: a systematic review. Malays J. Med. Sci. 31 (6), 77–102. doi:10.21315/mjms2024.31.6.7
Olufunmilayo, E. O., Gerke-Duncan, M. B., and Holsinger, R. M. D. (2023). Oxidative stress and antioxidants in neurodegenerative disorders. Antioxidants 12 (2), 517. doi:10.3390/antiox12020517
Ooi, H., and Welch, C. (2024). Obstacles to the early diagnosis and management of sarcopenia: current perspectives. Clin. Interv. Aging 19, 323–332. doi:10.2147/CIA.S438144
Palacz-Wrobel, M., Borkowska, P., Paul-Samojedny, M., Kowalczyk, M., Fila-Danilow, A., Suchanek-Raif, R., et al. (2017). Effect of apigenin, kaempferol and resveratrol on the gene expression and protein secretion of tumor necrosis factor alpha (TNF-α) and interleukin-10 (IL-10) in RAW-264.7 macrophages. Biomed. Pharmacother. 93, 1205–1212. doi:10.1016/j.biopha.2017.07.054
Pan, C., Yang, Y., Zhao, Z., and Hu, J. (2025). Combined effects of natural products and exercise on apoptosis pathways in obesity-related skeletal muscle dysfunction. Apoptosis 30 (3–4), 537–552. doi:10.1007/s10495-024-02069-7
Pedauyé-Rueda, B., García-Fernández, P., Maicas-Pérez, L., Maté-Muñoz, J. L., and Hernández-Lougedo, J. (2024). Different diagnostic criteria for determining the prevalence of sarcopenia in older adults: a systematic review. J. Clin. Med. 13 (9), 2520. doi:10.3390/jcm13092520
Pérez-Jiménez, J., Fezeu, L., Touvier, M., Arnault, N., Manach, C., Hercberg, S., et al. (2011). Dietary intake of 337 polyphenols in French adults. Am. J. Clin. Nutr. 93 (6), 1220–1228. doi:10.3945/ajcn.110.007096
Perrone, P., De Rosa, C., and D’Angelo, S. (2025). Polyphenols and bone health: a comprehensive review of their role in osteoporosis prevention and treatment. Molecules 30 (21), 4154. doi:10.3390/molecules30214154
Rajendran, P., Abdelsalam, S. A., Renu, K., Veeraraghavan, V., Ben Ammar, R., and Ahmed, E. A. (2022). Polyphenols as potent epigenetics agents for cancer. Int. J. Mol. Sci. 23 (19), 11712. doi:10.3390/ijms231911712
Rana, A., Samtiya, M., Dhewa, T., Mishra, V., and Aluko, R. E. (2022). Health benefits of polyphenols: a concise review. J. Food Biochem. 46 (10), e14264. doi:10.1111/jfbc.14264
Rayalam, S., Della-Fera, M. A., and Baile, C. A. (2011). Synergism between resveratrol and other phytochemicals: implications for obesity and osteoporosis. Mol. Nutr. Food Res. 55 (8), 1177–1185. doi:10.1002/mnfr.201000616
Rudrapal, M., Khairnar, S. J., Khan, J., Dukhyil, A. B., Ansari, M. A., Alomary, M. N., et al. (2022). Dietary polyphenols and their role in oxidative stress-induced human diseases: insights into protective effects, antioxidant potentials and mechanism(s) of action. Front. Pharmacol. 13, 806470. doi:10.3389/fphar.2022.806470
Russo, G. L., Vastolo, V., Ciccarelli, M., Albano, L., Macchia, P. E., and Ungaro, P. (2017). Dietary polyphenols and chromatin remodeling. Crit. Rev. Food Sci. Nutr. 57 (12), 2589–2599. doi:10.1080/10408398.2015.1062353
Salucci, S., and Falcieri, E. (2020). Polyphenols and their potential role in preventing skeletal muscle atrophy. Nutr. Res. 74, 10–22. doi:10.1016/j.nutres.2019.11.004
Sayer, A. A., and Cruz-Jentoft, A. (2022). Sarcopenia definition, diagnosis and treatment: consensus is growing. Age Ageing 51 (10), afac220. doi:10.1093/ageing/afac220
Shaito, A., Posadino, A. M., Younes, N., Hasan, H., Halabi, S., Alhababi, D., et al. (2020). Potential adverse effects of resveratrol: a literature review. Int. J. Mol. Sci. 21 (6), 2084. doi:10.3390/ijms21062084
Sirše, M. (2022). Effect of dietary polyphenols on osteoarthritis—molecular mechanisms. Life 12 (3), 436. doi:10.3390/life12030436
Sligar, J., DeBruin, D. A., Saner, N. J., Philp, A. M., and Philp, A. (2022). The importance of mitochondrial quality control for maintaining skeletal muscle function across health span. Am. J. Physiol-Cell Physiol. 322 (3), C461–C467. doi:10.1152/ajpcell.00388.2021
Su, Y. C., Chang, S. F., and Tsai, H. C. (2022). The relationship between sarcopenia and injury events: a systematic review and meta-analysis of 98,754 older adults. J. Clin. Med. 11 (21), 6474. doi:10.3390/jcm11216474
Sun, Q., Jiang, X., Qin, R., Yang, Y., Gong, Y., Wang, K., et al. (2022). Sarcopenia among older patients with cancer: a scoping review of the literature. J. Geriatr. Oncol. 13 (7), 924–934. doi:10.1016/j.jgo.2022.03.008
Tang, H., Inoki, K., Brooks, S. V., Okazawa, H., Lee, M., Wang, J., et al. (2019). mTORC1 underlies age-related muscle fiber damage and loss by inducing oxidative stress and catabolism. Aging Cell 18 (3), e12943. doi:10.1111/acel.12943
Tokuda, Y., and Mori, H. (2023). Essential amino acid and tea catechin supplementation after resistance exercise improves skeletal muscle mass in older adults with sarcopenia: an open-label, pilot, randomized controlled trial. J. Am. Nutr. Assoc. 42 (3), 255–262. doi:10.1080/07315724.2022.2025546
Ullah, H., De Filippis, A., Santarcangelo, C., and Daglia, M. (2020). Epigenetic regulation by polyphenols in diabetes and related complications. Mediterr. J. Nutr. Metab. 13 (4), 289–310. doi:10.3233/mnm-200489
Veronesi, F., Salamanna, F., Borsari, V., Ruffilli, A., Faldini, C., and Giavaresi, G. (2024). Unlocking diagnosis of sarcopenia: the role of circulating biomarkers – a clinical systematic review. Mech. Ageing Dev. 222, 112005. doi:10.1016/j.mad.2024.112005
Voulgaridou, G., Tyrovolas, S., Detopoulou, P., Tsoumana, D., Drakaki, M., Apostolou, T., et al. (2024). Diagnostic criteria and measurement techniques of sarcopenia: a critical evaluation of the up-to-date evidence. Nutrients 16 (3), 436. doi:10.3390/nu16030436
Wang, Y., Liu, Z., Shu, S., Cai, J., Tang, C., and Dong, Z. (2020). AMPK/mTOR signaling in autophagy regulation during cisplatin-induced acute kidney injury. Front. Physiol. 11, 619730. doi:10.3389/fphys.2020.619730
Wang, H., Yang, R., Xu, J., Fang, K., Abdelrahim, M., and Chang, L. (2021). Sarcopenia as a predictor of postoperative risk of complications, mortality and length of stay following gastrointestinal oncological surgery. Ann. R. Coll. Surg. Engl. 103 (9), 630–637. doi:10.1308/rcsann.2021.0082
Wang, M., Wang, B., Wang, S., Lu, H., Wu, H., Ding, M., et al. (2021). Effect of quercetin on lipids metabolism through modulating the gut microbial and AMPK/PPAR signaling pathway in broilers. Front. Cell Dev. Biol. 9, 616219. doi:10.3389/fcell.2021.616219
Wang, K., Liu, H., Hu, Q., Wang, L., Liu, J., Zheng, Z., et al. (2022). Epigenetic regulation of aging: implications for interventions of aging and diseases. Signal Transduct. Target Ther. 7 (1), 374. doi:10.1038/s41392-022-01211-8
Wang, J., Li, Y., Yang, G. Y., and Jin, K. (2025). Age-related dysfunction in balance: a comprehensive review of causes, consequences, and interventions. Aging Dis. 16 (2), 714–737. doi:10.14336/AD.2024.0124-1
Xu, X., and Wen, Z. (2023). The mediating role of inflammaging between mitochondrial dysfunction and sarcopenia in aging: a review. Am. J. Clin. Exp. Immunol. 12 (6), 109–126.
Xue, Q., Wu, J., Ren, Y., Hu, J., Yang, K., and Cao, J. (2021). Sarcopenia predicts adverse outcomes in an elderly population with coronary artery disease: a systematic review and meta-analysis. BMC Geriatr. 21 (1), 493. doi:10.1186/s12877-021-02438-w
Yadav, E., Yadav, P., Khan, M. M. U., Singh, H., and Verma, A. (2022). Resveratrol: a potential therapeutic natural polyphenol for neurodegenerative diseases associated with mitochondrial dysfunction. Front. Pharmacol. 13, 922232. doi:10.3389/fphar.2022.922232
Yang, S., Sun, M., and Zhang, X. (2022). Protective effect of resveratrol on knee osteoarthritis and its molecular mechanisms: a recent review in preclinical and clinical trials. Front. Pharmacol. 13, 921003. doi:10.3389/fphar.2022.921003
Yasunobu, T., and Mori, H. (2021). Effect of ingestion of essential amino acids and tea catechins after resistance exercise on the muscle mass, physical performance, and quality of life of healthy older people: a randomized controlled trial. Asia Pac J. Clin. Nutr. 30 (2), 213–233. doi:10.6133/apjcn.202106_30(2).0005
Yedigaryan, L., Gatti, M., Marini, V., Maraldi, T., and Sampaolesi, M. (2022). Shared and divergent epigenetic mechanisms in cachexia and sarcopenia. Cells 11 (15), 2293. doi:10.3390/cells11152293
Yuan, S., and Larsson, S. C. (2023). Epidemiology of sarcopenia: prevalence, risk factors, and consequences. Metabolism 144, 155533. doi:10.1016/j.metabol.2023.155533
Zeng, Z., Liang, J., Wu, L., Zhang, H., Lv, J., and Chen, N. (2020). Exercise-induced autophagy suppresses sarcopenia through Akt/mTOR and Akt/FoxO3a signal pathways and AMPK-mediated mitochondrial quality control. Front. Physiol. 11, 583478. doi:10.3389/fphys.2020.583478
Keywords: epigenetics, muscle aging, nutrigenomics, polyphenols, sarcopenia
Citation: Da Silva Rodrigues G, Lopes da Silva LS, Crystine da Silva Sobrinho A, Benjamim J, Abud GF, Ortiz GU, Cristini de Freitas E and Bueno Júnior CR (2026) Dietary polyphenols and sarcopenia: epigenetic mechanisms and geroscience perspectives for muscle health in aging. Front. Aging 6:1696473. doi: 10.3389/fragi.2025.1696473
Received: 31 August 2025; Accepted: 04 December 2025;
Published: 06 January 2026.
Edited by:
Marco P Brotto, University of Texas at Arlington, United StatesReviewed by:
Eduardo Abreu, University of Missouri–Kansas City, United StatesAndré Luis Shinohara, Faculdade de Odontologia da Universidade de São Paulo, Brazil
Copyright © 2026 Da Silva Rodrigues, Lopes da Silva, Crystine da Silva Sobrinho, Benjamim, Abud, Ortiz, Cristini de Freitas and Bueno Júnior. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Guilherme Da Silva Rodrigues, Z3Vpcm9kcmlndWVzQHVzcC5icg==
†These authors have contributed equally to this work